Public Disclosures Use of Names Sample Clauses

Public Disclosures Use of Names. Neither party will use the name or logos of the other party in any public announcement, advertising or other public disclosure regarding the relationship of the parties, the existence or contents of this Agreement, or this Study without the prior written approval of the other party, and Institution will ensure that each subcontractor will not make any such disclosure. Institution will provide Pfizer reasonable advance notice, and in any event at least 14 days’ notice, before publicly releasing any information about this Agreement or the Study (including, but not limited to, listings on clinical trial registries, website postings, press releases or presentations at scientific congresses) such that Pfizer may review and comment, and Institution will incorporate any reasonable Pfizer comments before releasing publicly.
AutoNDA by SimpleDocs
Public Disclosures Use of Names. 34 10.1 Press Releases and Other Public Disclosures 34 10.2 Use of Names 36 Article 11 Term; Termination 36 11.1 Term 36 11.2 Termination for Material Breach 36 11.3 Termination for Convenience 37 11.4 Effects of Termination or Expiration 37 11.5 Accrued Rights and Obligations 39 11.6 Survival 39 Article 12 Representations and Warranties 40 12.1 Array Representations and Warranties 40 12.2 Genentech Representations and Warranties 41 12.3 Disclaimers 42 Article 13 Indemnification; Limitation on Liability; Insurance 42 13.1 Indemnification 42 13.2 Limitation on Liability 44 13.3 Insurance 44 Article 14 Dispute Resolution 45 14.1 Internal Resolution 45 14.2 Arbitration 45 14.3 Subject Matter Exclusions 47 Article 15 Miscellaneous 47 15.1 Notices 47 15.2 Governing Law 49 15.3 Actions of Affiliates 49 15.4 Assignment 49 15.5 Force Majeure 49 15.6 Relationship of the Parties 50 15.7 Amendment; Waiver 50 EXHIBIT 10.57 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Public Disclosures Use of Names. 22 10.1 Press Releases and Other Public Disclosures. 22 10.2 Use of Names. 24 Article 11 Term; Termination 24 11.1 Term. 24 11.2 Termination for Material Breach. 24 11.3 Termination for Convenience. 24 11.4 Termination for Bankruptcy and Other Bankruptcy Matters 24 11.5 Effects of Termination or Expiration. 25 Article 12 Representations and Warranties 26 12.1 PTI Representations and Warranties. 26 12.2 Genentech Representations and Warranties. 28 12.3 Disclaimers. 28
Public Disclosures Use of Names. Neither party will use the name or logos of the other party in any public announcement, advertising or other public disclosure regarding the relationship of the parties, the existence or contents of this Agreement, or this Study/Registry without the prior written approval of the other party, and Grant Recipient will ensure that each subcontractor will not make any such disclosure. Grant Recipient will provide Pfizer reasonable advance notice, and in any event at least 14 days’ notice, before publicly releasing any information about this Agreement or the Study/Registry (including, but not limited to, listings on clinical trial registries, website postings, press releases or presentations at scientific Tato smlouva nahrazuje všechny předchozí dohody mezi smluvními stranami (ústní a písemné) týkající se této Studie/Registru, s výjimkou povinností, které v souladu s jejich podmínkami přetrvají nezávisle na této Smlouvě. 10.4. Povinnosti přetrvávající po skončení platnosti smlouvy. Články 3, 4, 5, 6, a 10 přetrvají i po skončení platnosti této Smlouvy, spolu s jakýmkoli jiným ustanovením této Smlouvy, které ze své povahy a záměru zůstává v platnosti i po jejím skončení. 10.5.
Public Disclosures Use of Names 

Related to Public Disclosures Use of Names

  • Publicity/Use of Names Neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except for those disclosures expressly authorized under this Article 4. Following execution of this Agreement, either Party may issue a press release announcing the existence of this Agreement in form and substance agreed to in writing by both Parties, such agreement to not be unreasonably withheld or delayed. Each Party agrees not to issue any other press release or other public statement disclosing other information relating to this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided that Arvinas agrees that it shall be deemed reasonable for Pfizer to withhold its consent for the disclosure of any information related to a Target or a specific Compound or the amount of any payment made or to be made under this Agreement; and provided further that any disclosure which is required by Law or the rules of a securities exchange, as reasonably advised by the disclosing Party’s counsel, may be made subject to the following. Each Party agrees to provide to the other Party a copy of any public announcement regarding this Agreement or the subject matter thereof as soon as reasonably practicable under the circumstances prior to its scheduled release. Except under extraordinary circumstances or to the extent any such advance notice or notice period is not consistent with applicable Law, each Party shall provide the other with an advance copy of any such announcement at least [**] prior to its scheduled release. Each Party shall have the right to expeditiously review and recommend changes to any such announcement and, except as otherwise required by Law, the Party whose announcement has been reviewed shall remove any information the reviewing Party reasonably deems to be inappropriate for disclosure. The contents of any announcement or similar publicity which has been reviewed and approved by the reviewing Party can be re-released by either Party without a requirement for re-approval. In addition, except to the extent required by Laws in connection with patent enforcement activities conducted in accordance with Article 7, Pfizer shall not use the name “Yale” or “Yale University,” nor any variation or adaptation thereof, nor any trademark, trade name or other designation owned by Yale University, nor the names of any of its trustees, officers, faculty, students, employees or agents, for any purpose without the prior written consent of Yale University in each instance, such consent to be granted or withheld by Yale University in its sole discretion, except that Pfizer may state that it has sublicensed from Yale University one or more of the patents or applications comprising the Yale Licensed Patents.

  • Public Disclosures The Company shall not, nor shall it permit any Subsidiary to, disclose any Investor’s name or identity as an investor in the Company in any press release or other public announcement or in any document or material filed with any governmental entity (other than tax filings in the ordinary course), without the prior written consent of such Investor, unless such disclosure is required by applicable law or governmental regulations or by order of a court of competent jurisdiction, in which case prior to making such disclosure the Company shall give written notice to such Investor describing in reasonable detail the proposed content of such disclosure and shall permit such Investor to review and comment upon the form and substance of such disclosure.

  • Use of Names; Publicity The Trust shall not use the Distributor’s name in any offering material, shareholder report, advertisement or other material relating to the Trust, other than for the purpose of merely identifying and describing the functions of the Distributor hereunder, in a manner not approved by the Distributor in writing prior to such use, such approval not to be unreasonably withheld. The Distributor hereby consents to all uses of its name required by the SEC, any state securities commission, or any federal or state regulatory authority. The Distributor shall not use the name “Tidal ETF Trust” in any offering material, shareholder report, advertisement or other material relating to the Distributor, other than for the purpose of merely identifying the Trust as a client of Distributor hereunder, in a manner not approved by the Trust in writing prior to such use; provided, however, that the Trust shall consent to all uses of its name required by the SEC, any state securities commission, or any federal or state regulatory authority; and provided, further, that in no case shall such approval be unreasonably withheld. The Distributor will not issue any press releases or make any public announcements regarding the existence of this Agreement without the express written consent of the Trust. Neither the Trust nor the Distributor will disclose any of the economic terms of this Agreement, except as may be required by law.

  • No Public Disclosure The Company shall not disclose any holder of Investor Units’ name or identity as an investor in the Company in any press release or other public announcement or in any document or material filed with any governmental entity, without the prior written consent of such Person, unless such disclosure is required by applicable law or governmental regulations or by order of a court of competent jurisdiction, in which case prior to making such disclosure the Company shall give written notice to such Person describing in reasonable detail the proposed content of such disclosure and shall permit such Person to review and comment upon the form and substance of such disclosure.

  • Review of Public Disclosures All SEC filings (including, without limitation, all filings required under the Exchange Act, which include Forms 10-Q and 10-QSB, 10-K and 10K-SB, 8-K, etc) and other public disclosures made by the Company, including, without limitation, all press releases, investor relations materials, and scripts of analysts meetings and calls, shall be reviewed and approved for release by the Company’s attorneys and, if containing financial information, the Company’s independent certified public accountants.

  • Public Disclosure Unless otherwise required by law, prior to the ----------------- Effective Time, no disclosure (whether or not in response to an inquiry) of the subject matter of this Agreement shall be made by any party hereto unless approved by Parent and the Company prior to release, provided that such approval shall not be unreasonably withheld.

  • Certain Disclosures A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of 1) the structure of the Blue Cross and Blue Shield System; and 2) the independent nature of every licensee; and 3) the Controlled Affiliate's financial condition.

  • ADV Disclosure The Adviser has provided the Trust with a copy of its Form ADV as most recently filed with the Commission and will, promptly after filing any amendment to its Form ADV with the Commission, furnish a copy of such amendments to the Trust. The information contained in the Adviser’s Form ADV is accurate and complete in all material respects and does not omit to state any material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading.

  • Confidentiality; Public Disclosure Each of the parties hereto hereby agrees that the information obtained pursuant to the negotiation and execution of this Agreement shall be treated as confidential and not be disclosed to third parties who are not agents of one of the Parties to this Agreement.

  • Prohibition on Press Releases and Public Announcements The Company shall not issue press releases or engage in any other publicity, without the Representative’s prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1st) Business Day following the forty-fifth (45th) day after the Closing Date, other than normal and customary releases issued in the ordinary course of the Company’s business.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!